The Emergence of 3D Printing in Expanding Clinical Research and Pharmaceutical Compounding
Why Sustainable Biomanufacturing Must Start Earlier in The Process
Electronic Logs - The next phase of execution maturity in pharma
Maximising Patient Engagement in Clinical Trials
From Snapshots to Movies
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
How can bioprinting enable better drug discovery?
CEO, Axolotl Biosciences
Dr Stephanie Willerth is a biomedical engineer entrepreneur and thought leader in D bioprinting and neural tissue engineering As CEO of Axolotl Biosciences and a Full Professor at the University of Victoria she leads innovations in personalized medicine through bioink development and human tissue models Her work bridges academia and industry bringing groundbreaking research into realworld healthca...
Articles
Harnessing Plant Potential
Biotechnology has achieved remarkable milestones with plantbased production of biotherapeutics emerging as a compelling innovation Traditionally biotherapeutics have been manufactured through microbial fermentation or animal cell cultivation but plants offer a greener more costeffective alternative Thanks to advances in genetic engineering and biological processing
Research Insights
Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study
Abstract Background Transarterial chemoembolization TACE and sorafenib are the therapeutic standard for intermediate and advanced stage hepatocellular carcinoma HCC patients respectively High costs with adverse events AE of sorafenib might limit sorafenib dosage further affecting therapeutic response To at
Case Studies
Effect Of Process And Formulation Variables On The Preparation Of Parenteral Paclitaxel-loaded Biodegradable Polymeric Nanoparticles: A Co-surfactant Study
Abstract Recent years have seen significant effort devoted to formulate therapeutic agents in biocompatible nanocomposites such as nanoparticles nanocapsules micellar systems and conjugates as drug delivery systems Application of nanotechnology for diagnosis monitoring disease therapy and control of biological systems was referred to as nanomedicin
Techno Trends
Skyline Therapeutics Develops SKG0106, a Novel Gene Therapy Candidate
Skyline Therapeutics developed SKG a novel intravitreally delivered AAV gene therapy targeting neovascular agerelated macular degeneration nAMD
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Is Convex Dose Dependence A Side Effect That Multiple Drug Treatment Causes?
Y-h. Taguchi obtained Dr. Sci. of Physics from Tokyo Institute of Technology. He has published papers in major journals, including Scientific Reports and PLoS ONE,a monograph from Springer International and is serving as academic editors in journals including PLoS ONE, BMC Medical Genomics and Frontiers in Genetics:RNA.
TurkiTurki received a PhD in computer science from the New Jersey Institute of Technology. He has published papers in journals, including Expert Systems with Applications, Knowledge-Based Systems, and PLoS ONE. Dr. Turki is an editorial board member of Computers in Biology and Medicine and Sustainable Computing: Informatics and Systems.
Innovative Tool For Drug Design And Development
S.Subash awarded 2 best poster presentation awards and secured 1st place in Poster presentation. I published three articles in national and international peer reviewed journal. And, also attend many conferences to upgrade knowledge.
What Happens When a Doctor Steps into the Boardroom?
Dr. Kruti Mehta is healthcare professional and entrepreneur with experience spanning clinical practice, healthcare management, and patient-centric innovation. Through their leadership journey, they advocate evidence-based decision-making, ethical growth, and transformative approaches that bridge medical expertise with the evolving needs of healthcare and industry.
Dr. Dhwani Mehta is healthcare professional and entrepreneur with experience spanning clinical practice, healthcare management, and patient-centric innovation. Through their leadership journey, they advocate evidence-based decision-making, ethical growth, and transformative approaches that bridge medical expertise with the evolving needs of healthcare and industry.
Neoteric Solvents: A Paradigm Shift in Pharmaceutical Industrial Processes
Abhinab Goswamiis currently pursuing his Ph.D. from National Institute of Pharmaceutical Education and Research, Guwahati. He has published 01 research paper, 02 review articles and 01 book chapter in renowned journals/international book. His research focus lies in developing the neoteric solvents-based injectable dispersions for intra-auricular administration. He has also identified few neoteric solvents potential for converting them into nanomedicines.
Datta Maroti Pawde is currently pursuing his Ph.D. from National Institute of Pharmaceutical Education and Research, Guwahati. He has published 05 research papers, 05 review articles and 03 book chapters in renowned journals/international book. Using the dual drug-loaded emulsions at lab-and pilot-scale, the intraarticular injections are developed to treat inflammatory conditions produced at articular or periarticular structures.
Syed Nazrin Ruhina Rahman is currently pursuing her Ph.D. from National Institute of Pharmaceutical Education and Research, Guwahati. She has published 02 research papers, 06 review articles and 04 book chapters in renowned journals/international book. Her research focus lies in managing the dry-eye syndrome by the topical application of cyclosporin A-loaded cationic emulsions.
Faculty Member, SB College of Pharmacy
Tamilvanan Shunmugaperumal is currently working at National Institute of Pharmaceutical Education and Research, Guwahati. He has published 58 research papers, 24 review articles and 08 book chapters in renowned journals international book. He is also author of 07 international books and holding 04 granted patents, 03 copyrights materials, etc.. His industrial-oriented research resulted in transfer of cationic emulsion formula from lab to industry.
USN Murty is currently working as Director of National Institute of Pharmaceutical Education and Research, Guwahati. He is the man of antimalarial research especially finding molecular leads from plant sources. He holds more than 100 research papers, few review articles and granted patents along with copyrights materials. His articulation in bioinformatics subjects is remarkable and he is the ardent user of artificial intelligence and machine learning in health-related platform.
Schedule M guideline: Revision and its nationwide implementation
Dr. M. Aamir Mirza is working as an Assistant Professor in the Department of Pharmaceutics, Jamia Hamdard, an NIRF Rank 1 institute and a NAAC ‘A+” grade deemed to be University. He has a multifaceted career portfolio adorned with both industry and academic accomplishments. During his industry stay he became a seasoned scientist and dealt with challenging NCE/NDA development. He is on advisory boards of some international research-based companies of India, New Zealand and Europe. Academics and Research being close to his heart, he has published more than 110 manuscripts in the journals of international repute and has been granted 02 Indian patent and filed for 04. He has contributed several chapters in books published by reputed authors like Elsevier and Bentham. He is amongst the very few scientists globally who has an expertise in Humic substances research. A well-travelled scientist; he has delivered scientific addresses in countries like USA, Austria, Japan, Netherlands, Turkey, Estonia, Spain and Russia. He has been Elite Fellow at University of Malaya (Malaysia) for the last 5 years where he takes classes on the topics related to industrial pharmacy.
press releasesRead more...
Chai Discovery Announces Collaboration with Roche in AI-Driven Drug Discovery
Chai Discovery the AI company building a computeraided design suite for proteinbased therapeutics today announced a collaboration with Roche to use Chais AI models and platform in a number of drug discovery programs across its therapeutic areas
PharmAla Signs Agreement and Initiates R&D with Corealis Pharma for GMP Manufacturing of its patented ALA-002 Drug Product
PharmAla Biotech Holdings Inc a biotechnology company focused on the research development and manufacturing of MDXXclass molecules including its proprietary LaNeo MDMA announces that it has signed an agreement with Corealis Pharma Inc Corealis a GMPcompliant contract development
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
HUTCHMED China Limited announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of autoimmune hemolytic anemia AIHA Sovleplenib is a novel selective oral spleen tyrosine kinase Syk inhibitor
Abbott and Novo expand partnership to launch Plosbrio® broadening access to semaglutide for advanced diabetes care across Asia Pacific
Abbott the global healthcare leader and Novo a global leader in treatments for serious chronic diseases announced an expanded strategic collaboration to increase access to originator semaglutide for people living with type diabetes across Asia Pacific Under the agreement Abbott will commercialise
Zuellig Pharma Strengthens Clinical Sourcing Capabilities in China through Strategic Acquisition
Zuellig Pharma a leading healthcare solutions company in Asia announced the strategic acquisition of a specialized clinical supply facility in Hangzhou China strengthening its clinical sourcing capabilities to better support domestic and international clinical trials
Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
Teva Pharmaceutical Industries Ltd and Samsung Bioepis Co Ltd today announced that they have entered into a license and commercialization agreement for two FDAapproved immunology biosimilars infliximababda a biosimilar to Remicade infliximab and ETICOVO etanerceptykro a biosimilar to Enbrel etanerc...
EventsRead more...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
11 - 13
Nov 2026Frontiers in Cancer Science 2026
One Farrer Hotel,1 Farrer Park...
11 - 12
Nov 2026Medical Device Project and Portfolio Management
Chicago, IL, USA
16 - 17
Nov 2026Analytics for Smarter Decisions in Pharma
London, UK
24 - 25
Nov 2026BioPharma Deals - The Survival Series
Munich, Germany
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
LATEST NEWSRead more...
Johnson & Johnson Receives Approval for RYBREVANT FASPRO to Treat Advanced Head and Neck Cancer
Johnson Johnson has received accelerated approval from the US Food and Drug Administration FDA for RYBREVANT FASPRO amivantamab and hyaluronidaselpuj to treat adults with recurrent or metastatic head and neck squamous cell carcinoma HNSCC
Boehringer Ingelheim Enters into Partnership with SBP Group to Advance Next-Generation Cancer Therapies
Boehringer Ingelheim and Sino Biopharmaceutical SBP Group have entered into a multiprogram partnership to develop potential nextgeneration cancer treatments using antibodydrug conjugate ADC and Tcell engager TcE technologies
MindWalk Partners with Teva to Support Antibody Discovery Using AI
MindWalk has entered into a multiyear agreement with Teva Pharmaceuticals Australia to support antibody discovery and design optimisation using AI technology ReefIQ is MindWalks biological context platform for the life sciences sector powered by its HYFT technology The technology
CStone Enters into Collaboration with Kimia Therapeutics to Advance Clinical Development of Novel Oncology Drug
CStone Pharmaceuticals has entered into a clinical development collaboration with USbased Kimia Therapeutics to advance a potential firstinclass drug candidate targeting the DNA damage response DDR pathway which plays an important role in the survival of solid tumour cells
DKSH and The Baker Company Partner to Expand Cell Culture and Microbiology Research
DKSH Business Unit Technology has entered into an exclusive distribution agreement with The Baker Company to make its Baker Ruskinn range of controlledenvironment technologies available to laboratories across Thailand The partnership aims to improve access to equipment used in cell culture tissue c...
Fresenius Enters into Agreement with WuXi Biologics to Expand Biosimilars Pipeline
Fresenius has entered into an exclusive development agreement with WuXi Biologics to expand its biosimilars pipeline and strengthen its biopharmaceutical business The partnership will give Fresenius access to WuXi Biologics capabilities in biologics research development and manufacturing
